drugset / Trial / NCT05706870

Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis

NCT05706870 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerability of GN-037 versus clobetasol 17-propionate and placebo in patients diagnosed with mild to moderate plaque psoriasis at least 6 months ago

Timeline

Start
2022-12-07
Primary completion
2024-01-04
Completion
2024-03-03

Outcome

Met primary endpoint

paper GN-037 demonstrated statistically significant superiority over V throughout the study. PMID 39578347 ↗

paper GN-037 was more effective than V in achieving primary and all secondary endpoints throughout the study. PMID 39578347 ↗

release “Yenilikçi topikal kremimiz ile gerçekleştirdiğimiz Faz 2 klinik araştırmamızda tüm primer ve sekonder sonlanım noktaları bakımından GN-037 kreminin plaseboya göre daha üstün sonuçlar sağladığı” com.tr ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject GN-037 Unknown — Topical
Comparator clobetasol propionate Small molecule — Topical

Indications